About IAC
A-Z Index
Immunization Action Coalition
IAC Home
Ask the Experts
Question of the Week

Ask the Experts

Question of the Week

December 2016 Back to top
December 21, 2016
Can the meningococcal serogroup B (MenB) vaccine and meningococcal conjugate (MenACWY) vaccine be given at the same visit?
MenB and MenACWY vaccines can be administered at the same visit or at any interval before or after each other. There is no need for spacing between these two vaccines.
Question of the Week: IAC Express - Issue 1282
December 14, 2016
My healthy 29-year-old son recently had a mild episode of herpes zoster. He has no underlying medical problems. He was treated with famcyclovir. Should he now get zoster vaccine?
The Advisory Committee on Immunization Practices (ACIP) does not recommend zoster vaccine for persons younger than 60 years of age regardless of their history of zoster. The currently available vaccine is licensed for persons 50 years and older. A clinician may choose to give the vaccine to a person younger than 50 years, but such use would be off-label.
Question of the Week: IAC Express - Issue 1280
December 7, 2016
For our "Mother's Day Out" program, one of the teachers has shingles. The program serves moms of 2-month-olds to 4-year-olds. All children are up to date with their vaccinations, but some are too young to have received varicella vaccine. Is it safe for the teacher to work?
In a school setting, an immunocompetent person with zoster (staff or students) can remain at school as long as the lesions can be completely covered. People with zoster should be careful about personal hygiene, wash their hands after touching their lesions, and avoid close contact with others. If the lesions cannot be completely covered and close contact avoided, the person should be excluded from the school setting until the zoster lesions have crusted over. See www.cdc.gov/chickenpox/outbreaks/manual.html for more information.

If your program is licensed by a state or county, you should check their regulations as well.
Question of the Week: IAC Express - Issue 1279
November 2016 Back to top
November 30, 2016
Why are zoster, pneumococcal polysaccharide (PPSV23) and meningococcal serogroup B (MenB) vaccines not covered by the National Vaccine Injury Compensation Program?
The National Vaccine Injury Compensation Program includes payment only for injuries determined to have occurred following vaccination with a vaccine routinely recommended for children in the United States. The recipient can be of any age, but the vaccine must be routinely recommended for children and teens through age 18 years. Zoster, PPSV23 and MenB vaccines are not routinely recommended for children. Zoster is only licensed and recommended for adults. PPSV23 and MenB vaccines are routinely recommended only for select high-risk groups of children and adults. More information about the program and the covered vaccines is at www.hrsa.gov/vaccinecompensation/coveredvaccines/index.html.
Question of the Week: IAC Express - Issue 1277
November 23, 2016
Is there any contraindication to administering Tdap vaccine and Rhogam at the same time to a pregnant woman?
No. Tdap is an inactivated vaccine and may be administered at the same time as Rhogam (in a separate site with a separate syringe).
Question of the Week: IAC Express - Issue 1276
November 16, 2016
Several healthy adult college students from Asia (ages 24 years and older) presented to our clinic. They will be living in a residence hall. None have a record of having received meningococcal conjugate vaccine (MenACWY). Should they receive a dose of MenACWY now?
ACIP does not routinely recommend MenACWY for college students 22 years of age and older. It is recommended for previously unvaccinated first-year college students who are age 21 years and younger who are or will be living in a residence hall. However, some colleges and universities may require incoming freshmen and others to be vaccinated with MenACWY and some may also require that a dose have been given after 16 years of age.
Question of the Week: IAC Express - Issue 1275
November 9, 2016
An adolescent received the first dose of hepatitis B vaccine at age 11 years but did not return for subsequent doses. If the patient comes back at age 16 years, is it necessary to repeat the first dose of the series?
It is not necessary to restart or add doses to the hepatitis B series (or any other routine vaccine series) because of a prolonged interval between doses. Just continue the series from the point where it was interrupted.
Question of the Week: IAC Express - Issue 1274
November 2, 2016
A 32-year-old patient with ulcerative colitis is taking high-dose immunosuppressive medications (6-mercaptopurine). Should he receive meningococcal vaccine?
There is no specific indication for meningococcal vaccine in this patient. He is older than 21 years, and the risk–based recommendations are restricted to specific forms of altered immunocompetence (persistent complement component deficiency, functional or anatomic asplenia, use of eculizumab and HIV infection) and are not inclusive of other forms of altered immunocompetence.
Question of the Week: IAC Express - Issue 1273
October 2016 Back to top
October 26, 2016
We have a patient who has selective IgA deficiency. We also have patients with selective IgM deficiency. Can MMR or varicella vaccine be administered to these patients?
There is no known risk associated with MMR or varicella vaccination in someone with selective IgA or IgM deficiency. It is possible that the immune response may be weaker, but the vaccines are likely effective.
Question of the Week: IAC Express - Issue 1272
October 19, 2016
I've seen the recommendation stating air bubbles in manufacturer-filled syringes do not need to be expelled. Can you explain why those air bubbles can be injected but air bubbles in user-filled syringes must be expelled?
It is not wrong to expel the air from syringes filled by manufacturers, but typically it is such a small amount of air (0.2cc–0.3cc) that it is our opinion that it would not cause a problem. When the syringe is inverted during an injection, that small amount of air would typically just clear the medication from the needle. This is based on the recommendation that when the Z-track method is used for intramuscular injection of irritating medication (e.g., iron preparations), the guidance is to leave 0.2cc–0.3cc in the syringe to be sure that all of the medication leaves the needle and is not tracked back through subcutaneous tissue as the needle is withdrawn. While the Z-track injection technique is not recommended for vaccine administration, the Z-track method demonstrates the acceptability of leaving a very small amount of air in the syringe for intramuscular injections.

We do, however, recommend that when drawing vaccine from a vial into a regular syringe, the air be expelled because the amount of air drawn into the syringe may be larger than the amount in a manufacturer-filled syringe. Expelling the air is part of general medication guidelines for drawing medication into a syringe.
Question of the Week: IAC Express - Issue 1270
October 12, 2016
I have an 8-month-old patient who is traveling internationally. The infant needs immune globulin (IG) for hepatitis A protection as well as MMR vaccine. The family is leaving in 11 days. Can I give the IG and the MMR vaccine simultaneously?
IG may contain antibodies to measles, mumps, and rubella that could reduce the effectiveness of MMR vaccine. The best course of action is to administer the MMR vaccine and defer the IG. Once the vaccine is given, an antibody-containing blood product like IG can be administered two weeks later. While it may be difficult to get this product administered before leaving, you are better off than if IG were administered first, as a 3-month interval is recommended between IG and MMR.
Question of the Week: IAC Express - Issue 1269
October 5, 2016
Mom comes in with her 19-month-old. She reports that her (the mother’s) sibling has a history of a severe reaction to pertussis vaccine in the mid 1990s. Now mom is reluctant to give her child pertussis vaccine although the child received Pediarix (DTaP-HepB-IPV, GlaxoSmithKline) 2 months ago without incident. Should we be concerned about the mother’s family history of a severe reaction to pertussis vaccine?
A family history of a neurologic disorder or reaction to a pertussis-containing vaccine is not a contraindication to vaccination of this child. The child should receive additional DTaP doses as indicated in the catchup schedule.
Question of the Week: IAC Express - Issue 1268
September 2016 Back to top
September 28, 2016
Is it acceptable to write the expiration date (the “Beyond Use Date”) of an opened vaccine multi-dose vial on the box rather than the vial or must it be written on the vial?
It is acceptable to put the Beyond Use Date (BUD) on the packaging; this may help when reviewing inventory. But a provider should always read the label on the vial before administering a vaccine. It is possible for a vial to be placed in the wrong box. So the vial label is the safest place to put the BUD. Vial labels are small and it may require putting an extra sticky label on the vial.
Question of the Week: IAC Express - Issue 1267
September 21, 2016
With the ACIP recommendation to not use live attenuated influenza vaccine (LAIV, FluMist, AstraZeneca) during the 2016–2017 season will there be enough inactivated influenza vaccine (IIV) to meet the demand for the upcoming season?
Influenza vaccine manufacturers project that as many as 171 to 176 million doses of influenza vaccine will be available for the 2016–2017 season. LAIV accounts for up to 14 million of those doses (about 8% of the total supply). Based on manufacturer projections, health officials expect that supply of IIV for the 2016–2017 season should be sufficient to meet any increase in demand resulting from the ACIP recommendation, though providers may need to check more than one supplier or purchase a vaccine brand other than the one they normally select.
Question of the Week: IAC Express - Issue 1266
September 14, 2016
I know that live attenuated influenza vaccine (LAIV, FluMist) is not recommended to be used this season. If a dose of LAIV is administered this year, does it count or should we repeat it with inactivated influenza vaccine?
The dose can be counted. It does not need to be repeated with inactivated influenza vaccine.
Question of the Week: IAC Express - Issue 1265
September 7, 2016
Why should we not give PCV13 vaccine to someone who has had a serious reaction to a diphtheria-containing vaccine in the past?
PCV13 vaccine is conjugated to a type of diphtheria-toxoid. So if someone has a past history of anaphylaxis following diphtheria-containing vaccine, it might be due to the diphtheria toxoid, and the cause of the anaphylactic allergy should be identified before the administration of PCV13 vaccine. This could be difficult since no single-antigen diphtheria toxoid is available in the U.S. Fortunately, true anaphylactic allergy to diphtheria-containing vaccine is rare.
Question of the Week: IAC Express - Issue 1264
August 2016 Back to top
August 24, 2016
When not given on the same day, is the interval between yellow fever and MMR vaccines 4 weeks (28 days) or 30 days? I have seen the yellow fever and live virus vaccine recommendations published both ways.
The General Recommendations on Immunization makes the generic recommendation that live parenterally or nasally administered vaccines not given on the same day should be separated by at least 28 days. The CDC travel health website recommends that yellow fever vaccine and other parenteral or nasal live vaccines should be separated by at least 30 days if possible.
Question of the Week: IAC Express - Issue 1262
August 17, 2016
If a six-year-old child is due for the fifth dose of DTaP and inadvertently receives Tdap, I know that this dose counts as the fifth dose of DTaP. But should this child receive another dose of Tdap at age 11–12 years?
Yes. In this situation, a second dose of Tdap should be administered at the recommended age of 11 or 12 years.
Question of the Week: IAC Express - Issue 1261
August 10, 2016
The ACIP recommendations for meningococcal serogroup B (MenB) vaccine say the vaccine will provide “short term protection.” What does “short term protection” mean?The ACIP recommendations for meningococcal serogroup B (MenB) vaccine say the vaccine will provide “short term protection.” What does “short term protection” mean?
MenB vaccines were approved based on the serologic response to the vaccine. No data are available on vaccine effectiveness against clinical disease or duration of protection against clinical disease. Short term protection refers to the known duration of the antibody response. Available data indicate that a protective antibody level should persist in most recipients for 24 to 48 months after vaccination. This issue will continue to be monitored. For more information, see www.cdc.gov/mmwr/pdf/wk/mm6441.pdf, pages 1171–5.
Question of the Week: IAC Express - Issue 1260
August 3, 2016
I gave a dose of ActHIB vaccine to a 15-month-old that was reconstituted with Menveo diluent. Can I count the dose? What are the possible side effects I should be concerned with?
Vaccines should be reconstituted according to manufacturer guidelines using only the diluent supplied by the manufacturer for that vaccine. Each diluent is specific to the corresponding vaccine in volume, pH, and chemical balance. If the wrong diluent is used, the vaccine dose is not valid and should be repeated using the correct diluent. Although there are no safety data for ActHib reconstituted with the wrong diluent, a significant adverse reaction, other than possibly a local reaction, seems unlikely.
Question of the Week: IAC Express - Issue 1258
July 2016 Back to top
July 27, 2016
If my patient is taking Tamiflu (oseltamivir), can she receive zoster vaccine?
Yes. Although oseltamivir is an antiviral drug, it is only effective against influenza A and B viruses. Zoster vaccine contains varicella zoster virus which is not affected by oseltamivir.
Question of the Week: IAC Express - Issue 1257
July 20, 2016
In a mumps outbreak, should we offer a third dose of MMR to persons who have two prior documented doses of MMR?
You should consult with the local health department about the necessity for a third dose of mumps-containing vaccine in this circumstance. Currently, data are insufficient to recommend for or against the routine use of a third dose of MMR vaccine for mumps outbreak control. CDC has issued guidance for considerations for use of a third dose in specifically identified target populations along with criteria for public health departments to consider in decision making. This information can be found at www.cdc.gov/vaccines/pubs/surv-manual/chpt09-mumps.html.
Question of the Week: IAC Express - Issue 1256
July 13, 2016
I have patients who are in their 70s or 80s and remember getting a pneumococcal vaccine “a few years ago.” Should I assume that this was PPSV23? Should I assume that it was given before the 65th birthday?
You can accept a verbal report of PPSV23. Since the recommendation for routine vaccination with PCV13 is relatively recent (November 2014) it is reasonable to assume that PPSV23 was the pneumococcal vaccine that was administered earlier. Try to ascertain how long ago it was given. If you think the dose was given after the 65th birthday and it has been a year since the dose was administered, give a dose of PCV13 now. If the dose was administered before the 65th birthday, administer a dose of PCV13 now, and then administer a dose of PPSV23 one year later, assuming that it has been 5 years since the first dose of PPSV23 was administered.
Question of the Week: IAC Express - Issue 1255
July 6, 2016
The meningococcal conjugate vaccine recommendations state that a routine second dose of meningococcal conjugate (MenACWY) vaccine needs to be given at 16 years of age. Children with asplenia or other high-risk conditions should receive a booster dose every 5 years. If a child with a high-risk condition receives a dose of MenACWY at age 9 years (and a second primary dose 8 weeks later), should they receive a booster dose at age 14 years (5 years after the primary series), or should they receive a dose at age 16 years as recommended in the routine schedule?
The MenACWY booster dose should be given at 14 years (5 years after the primary series) and every 5 years thereafter. The every 5-year booster dose schedule for persons with high-risk conditions takes precedent over the routine second dose schedule.
Question of the Week: IAC Express - Issue 1254
June 2016 Back to top
June 29, 2016
We did a hepatitis B panel for a new hospital employee from Gambia. She had no documentation of having been vaccinated. Her results showed HBsAg nonreactive, anti-HBc reactive, IgM anti-HBc nonreactive, and anti-HBs borderline. We don’t know how to interpret these results. Should she be immunized?
Most likely this person has a resolved hepatitis B infection and is immune. However, it would be preferable to test her again for all these serologic markers, and also quantify the anti-HBs result. If the results are still positive for anti-HBc, and anti-HBs is less than the immune level of 10mIU/mL, you can give her one dose of hepatitis B vaccine and test again in 1–2 months. If the anti-HBs is positive (10 mIU/mL or higher), she is immune. No further action is needed other than to document the results. If the anti-HBs is still negative, complete the vaccine series and test again 1–2 months after the last dose of vaccine.
If she is still anti-HBs negative after 3 doses of vaccine, test again for HBsAg to be sure she is not chronically infected (unlikely) and counsel her as a nonresponder. See www.cdc.gov/mmwr/pdf/rr/rr6210.pdf for more information about hepatitis B vaccination of healthcare personnel. Information about persons with isolated positive anti-HBc is available at www.cdc.gov/hepatitis/hbv/hbvfaq.htm#general.
Question of the Week: IAC Express - Issue 1253
June 22, 2016
Is the top shelf of a pharmacy-grade storage unit acceptable for vaccine storage if there is a fan directly above it?
Generally speaking, CDC recommends avoiding the top shelf and the areas near vents due to temperature fluctuations. However, most pharmaceutical-grade units have more uniform temperatures than household units under normal operating conditions. During a power outage, the top shelf is an area of caution for all units as the temperatures increase most quickly there. In this instance, it would be best to check with the manufacturer to see if the top shelf is appropriate for storage in your unit.
Question of the Week: IAC Express - Issue 1252
June 15, 2016
We have a 20-week-old infant who was born prematurely. The infant has never received rotavirus vaccine and is technically past the maximum age for first dose. Should we give rotavirus vaccine to this infant?
ACIP recommends vaccination of preterm infants according to the same schedule and precautions as full-term infants. In preterm infants (as in full-term infants), the maximum chronological age for the first dose is 14 weeks 6 days. Vaccination should not be initiated for infants aged 15 weeks 0 days or older because of insufficient data on safety of dose 1 of rotavirus vaccine in older infants. For more information, see page 19 of ACIP's recommendations on rotavirus vaccination.
Question of the Week: IAC Express - Issue 1251
June 8, 2016
My 7-year-old patient has had only 1 dose of tetanus toxoid-containing vaccine at 11 months of age (a dose of DTaP). The catch-up schedule says he needs 3 additional doses of tetanus toxoid-containing vaccine (4 total). Why 4? If he were completely unvaccinated on the seventh birthday, he would only need a total of 3 doses.
If the first dose of a tetanus toxoid-containing vaccine is administered before the first birthday, 4 doses are necessary before beginning the 10-year cycle of booster doses. If the first dose is administered after the first birthday, 3 doses are necessary. The final dose should be spaced 6 months from the previous dose.
Question of the Week: IAC Express - Issue 1250
June 1, 2016
A child was inadvertently administered the first dose of rotavirus vaccine at five months of age. Since the rotavirus vaccine series was started after age 15 weeks, should the series be continued?
If a child inadvertently receives the first dose of rotavirus vaccine at 15 weeks or older, the remaining doses of the series can be given as long as they are administered by 8 months and 0 days of age. However, if the child is already 8 months and 1 day or older, ACIP does not recommend giving any further doses because 8 months and 0 days is the maximum age for administering any dose in the series. See page 17 of Prevention of Rotavirus Gastroenteritis Among Infants and Children Recommendations of the Advisory Committee on Immunization Practices (ACIP) for more information.
Question of the Week: IAC Express - Issue 1248
May 2016 Back to top
May 25, 2016
A provider has a 54-year-old woman with rheumatoid arthritis who had been on etanercept (Embrel) at a dose of 50 mg per week. The etanercept was stopped two weeks ago. What is the interval between stopping etanercept and receiving zoster vaccine?
The safety and efficacy of zoster vaccine administered concurrently with recombinant human immune mediators and immune modulators (such as the anti-tumor necrosis factor agents adalimumab, infliximab, and etanercept) is not known. It is preferable to administer zoster vaccine before treatment with these drugs. Otherwise, administration of zoster vaccine (and other live vaccines) should be deferred for at least one month after discontinuation of treatment.
Question of the Week: IAC Express - Issue 1247
May 18, 2016
An expired dose of ProQuad (MMRV, Merck) was given to a patient. We assume that the repeat dose should be given in three months because the spacing between doses of a combination vaccine depends on the longest minimum interval of a component (in this case the varicella vaccine component). Is this correct?
In the case of an expired live vaccine, the issue is not necessarily the routine minimum interval (three months in the case of varicella and ProQuad vaccines), but the interval that would prevent viral interference if the expired vaccine happened to be still viable. This interval is considered to be four weeks (28 days). The repeat dose should be administered four weeks after the expired dose.
Question of the Week: IAC Express - Issue 1246
May 11, 2016
We have a 40 lb six-year-old patient who has been taking 15 mg of methotrexate weekly for arthritis for 12 months. Can we give the child MMR and varicella vaccine based on this methotrexate dosage?
Based on the weight and dosage provided (40 lbs and 15 mg/week), the child is currently receiving more than 0.4 mg/kg/week of methotrexate. This meets the Infectious Disease Society of America (IDSA) definition of high-level immunosuppression. Administration of both varicella and MMR vaccines are contraindicated until such time as the methotrexate dosage can be reduced.
The IDSA states that administration of varicella vaccine (but not MMR) can be considered for non-varicella-immune patients treated for chronic inflammatory disease who are receiving long-term low-dose immunosuppression. Low-dose immunosuppression for methotrexate is a dosage of less than 0.4 mg/kg/week. See Table 6 (and associated footnotes): cid.oxfordjournals.org/content/early/2013/11/26/cid.cit684.full.pdf.
Question of the Week: IAC Express - Issue 1245
May 4, 2016
If a patient has a history of cerebrospinal fluid (CSF) leak but no current leak, is this a risk factor and a reason to administer PCV13 and PPSV23 to an adult?
No. If there is no longer a CSF leak, neither vaccine is recommended, unless there is another risk factor for invasive pneumococcal disease or an age-based indication.
Question of the Week: IAC Express - Issue 1244
April 2016 Back to top
April 27, 2016
I have read that HPV vaccine should not be administered to pregnant women. Do we need to perform a pregnancy test prior to administering this vaccine to our patients? Currently, we ask about pregnancy prior to providing the vaccine.
HPV vaccines are not recommended for use in pregnant women. The vaccines have not been associated causally with adverse outcomes of pregnancy or adverse events in the developing fetus. However, if a woman is found to be pregnant after initiating the vaccination series, the remainder of the three-dose series should be delayed until completion of pregnancy. Pregnancy testing is not needed before vaccination. If a vaccine dose has been administered during pregnancy, no intervention is needed.
Question of the Week: IAC Express - Issue 1243
April 20, 2016
I have a female patient who has a non-immune rubella titer two months after her second MMR vaccination. Should she be revaccinated? If so, should the titer again be checked to determine seroconversion?
ACIP recommends that vaccinated women of childbearing age who have received one or two doses of rubella-containing vaccine and have a rubella serum IgG levels that is not clearly positive should be administered one additional dose of MMR vaccine (maximum of three doses). Repeat serologic testing for evidence of rubella immunity is not recommended. See http://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf, pages 18–20, for more information on this issue.
MMR vaccines should not be administered to women known to be pregnant or attempting to become pregnant. Because of the theoretical risk to the fetus when the mother receives a live virus vaccine, women should be counseled to avoid becoming pregnant for 28 days after receipt of MMR vaccine.
Question of the Week: IAC Express - Issue 1242
April 13, 2016
Zoster vaccine was inadvertently given to a patient taking Humira (adalimumab) 40 mg per week for rheumatoid arthritis. Because of the high dose, should the patient be started on antivirals as prophylaxis or should the patient just be monitored?
Although herpes zoster vaccine is contraindicated for patients taking biologic agents including tumor necrosis factor (TNF) antagonists (adalimumab is a TNF antagonist), vaccinating patients that are immunocompromised is unlikely to result in serious adverse events.
It is prudent to monitor your patient with a low threshold for any signs of adverse events (such as rash or fever), within one month after vaccination, but prophylactic antivirals are not indicated. Acyclovir, valacyclovir, and famciclovir are active against the vaccine virus and can be used in the unlikely situation in which illness develops.
Question of the Week: IAC Express - Issue 1241
April 6, 2016
We have a two-month-old male with his second episode of meningococcemia (group B). He is still undergoing an evaluation for primary immunodeficiency, but we are planning to proceed with immunizations, including meningococcal ACWY-CRM vaccine, but wanted to provide meningococcal B as well. Given that in the U.S., meningococcal B vaccine is only approved in children age 10 years and older, can we use it in the infant age group?
Use of either meningococcal serogroup B vaccine in persons younger than age 10 years is off-label in the U.S. There is currently no ACIP recommendation for use of this vaccine for this age group. However, Bexsero brand meningococcal B vaccine has been studied among infants and is approved for infants by the European Medicines Agency (the European version of the U.S. Food and Drug Administration). It is routinely recommended for infants in the United Kingdom (see www.nhs.uk/conditions/vaccinations/pages/meningitis-b-vaccine.aspx for details). A clinician may choose to use a vaccine off-label if, in their opinion, the benefit of the vaccine exceeds the risk from the vaccine. Product information for Bexsero can be found on the European Medicines Agency website at www.ema.europa.eu/ema.
Question of the Week: IAC Express - Issue 1240
March 2016 Back to top
March 30, 2016
I have a patient who is a medical student about to start clinical rotations. She has written documentation of two doses of varicella vaccine (the first at age 12 years and the second at age 26 years). Her varicella IgG is negative. Is she a non-responder? Should I give her a booster dose?
Titers are not necessary or recommended if there are documented doses of varicella vaccine. Commercial serologic tests may not be sensitive enough to detect vaccine-induced antibody. In this situation, a negative titer should be disregarded. The student should be considered immune because of her documented vaccination history. See ACIP's Immunization of Health-Care Personnel, pages 23–24, for more information on this issue.
Question of the Week: IAC Express - Issue 1238
March 23, 2016
Does an adult younger than age 65 years with beta thalassemia minor meet the criteria for a recommendation for vaccination with PCV13?
No. Beta thalassemia minor is a hemoglobinopathy, but compared to sickle cell disease, these patients have less risk for functional asplenia, and by extension a reduced risk for invasive pneumococcal disease.
Question of the Week: IAC Express - Issue 1236
March 16, 2016
We have a 61-year-old patient who is taking 500 mg of valacyclovir (Valtrex) daily. Can she receive zoster vaccine?
Acyclovir, famciclovir, and valacyclovir are antiviral drugs that are active against herpesviruses. These drugs' agents might interfere with replication of live zoster vaccine. All three drugs have relatively short serum half-lives and are quickly eliminated from the body. Persons taking acyclovir, famciclovir, or valacyclovir should discontinue the drug at least 24 hours before administration of zoster vaccine, if possible. The drug should not be taken again for at least 14 days after vaccination, by which time the immunologic effect of the vaccine should be established.
Question of the Week: IAC Express - Issue 1234
March 9, 2016
An adult patient with asplenia received Menactra two weeks after a dose of PCV13. Should the PCV13 dose be repeated?
Yes. ACIP recommends that for persons 2 through 55 years of age with a high-risk condition (asplenia or complement component deficiency), Menactra be administered at least 4 weeks after completion of all PCV13 doses. See the footnote of the table on page 16 here for more information on this issue.
Question of the Week: IAC Express - Issue 1233
March 2, 2016
I have a patient who is traveling internationally and needs MMR vaccine. He recently received an injectable steroid. How long should he wait before receiving MMR vaccine?
There is no need to wait a specific interval before giving MMR. Injectable steroids are not considered immunosuppressive for the purpose of vaccination decisions, and so there is no concern about safety or efficacy of MMR.
Question of the Week: IAC Express - Issue 1232
February 2016 Back to top
February 24, 2016
Although licensed by the Food and Drug Administration for use through age 4 years, a dose of Pentacel was inadvertently given to a six-year-old. Do any components of the Pentacel dose need to be repeated?
Pentacel (DTaP-IPV/Hib) inadvertently administered to children six years of age and older is considered a vaccine administration error. However, none of the vaccine components need to be repeated.
IAC Express - Issue 1231
February 17, 2016
Do we need to wait for the vaccine to reach room temperature before we administer it to a patient?
There is no recommendation to wait until a vaccine reaches room temperature before administration. The vaccine should be administered as soon as it is prepared.
IAC Express - Issue 1230
February 10, 2016
If someone is older than 55 years and had their spleen removed, are they recommended for meningococcal polysaccharide vaccine or meningococcal conjugate vaccine?
Meningococcal conjugate vaccines (MCV4) are licensed for persons through age 55 years. For persons older than 55 years with a high-risk medical condition (such as asplenia), the Advisory Committee on Immunization Practices (ACIP) recommends off-label use of MCV4. Asplenic persons should receive a primary series of two doses of MCV4 separated by eight weeks, followed by a dose every five years thereafter. These recommendations are available at www.cdc.gov/mmwr/pdf/rr/rr6202.pdf, page 15.
IAC Express - Issue 1229
February 3, 2016
We have an 18-year-old male who had a history of chickenpox disease. He now has shingles. We are unsure what we are to advise for future treatment. Should we administer zoster vaccine?
The Advisory Committee on Immunization Practice does not recommend zoster vaccination for people younger than age 60 years regardless of their history of shingles. Zoster vaccine is licensed by the Food and Drug Administration for people age 50 years and older so a clinician may choose to vaccinate a person 50 through 59 years of age. Insurance may not pay for a dose of zoster vaccine given to a person younger than age 60 years.
IAC Express - Issue 1228
January 2016 Back to top
January 27, 2016
What is the schedule for hepatitis B vaccination for infants weighing less than 2000 grams? I read that the birth dose should still be given in the hospital, but what would be the schedule after that?
Decreased seroconversion rates might occur among preterm infants with low birth (less than 2,000 grams) after administration of hepatitis B vaccine at birth. However, by the chronological age of one month, all preterm infants, regardless of initial birth weight, are likely to respond as adequately as larger infants.
Preterm infants born to HBsAg-positive women and women with unknown HBsAg status must receive hepatitis B vaccine within 12 hours after birth. The initial vaccine dose should not be counted toward completion of the hepatitis B series, and three additional doses of hepatitis B vaccine should be administered, beginning when the infant is age one month. For mothers with unknown HBsAg status, attempts should be made to determine HBsAg status. The infant also must be given HBIG within 12 hours of birth unless the mother is found to be HBsAg negative. Infants weighing less than 2,000 grams born to HBsAg-negative mothers should receive the first dose of the hepatitis B series at chronological age one month or at hospital discharge.
IAC Express - Issue 1226
January 20, 2016
An 86-year-old patient came in today and stated he needed a pneumococcal vaccine booster. He reports receiving a dose of "pneumonia vaccine" when he was 77 years old. Which pneumococcal should he receive today, PCV13 or PPSV23?
It is unlikely that the previous dose of pneumococcal vaccine was PCV13, since this vaccine was not routinely recommended for any adult population nine years ago. The patient most likely received pneumococcal polysaccharide vaccine (PPSV23). A dose of PCV13 should be given now. People who receive PPSV23 after age 65 years are not recommended to receive additional doses of PPSV23.
IAC Express - Issue 1225
January 13, 2016
If an egg-free influenza vaccine (FluBlok, Protein Sciences) was given inadvertently to a person younger than 18 years, can it be counted? Would there be any adverse side effects from this error?
Flublok is not licensed for persons younger than 18 years of age, so there are no data regarding safety and efficacy in this age group. However, no serious side effects would be expected. The dose does not need to be repeated. Even if no adverse reaction occurs, we request that vaccine administration errors like this be reported to the Vaccine Adverse Events Reporting System at www.vaers.hhs.gov.
IAC Express - Issue 1224
January 6, 2016
If a patient received Trumenba (MenB; Pfizer) two months ago and Bexsero (MenB, GSK) yesterday, should they complete the series with two additional doses of Trumenba or one more of Bexsero since the two brands are not interchangeable? What would be the interval from the Bexsero to the next dose?
The patient can complete the series with either vaccine. If Bexsero is chosen, the next dose (Bexsero #2) should be administered at least one month after yesterday’s dose. The Bexsero #2 would be the final dose. If Trumenba is chosen, the next dose (Trumenba #2) should be administered at least one month after yesterday’s Bexsero dose. The one-month interval between doses of Trumenba and Bexsero is recommended because one component (FHbp) is contained in both of the vaccine products and there is concern about potential interference. The final dose (Trumenba #3) should be administered four months after Trumenba #2.
IAC Express - Issue 1222
>> More Questions of the Week: 2015 Archive
Ask the Experts
Ask Experts Home Ask the Experts Home
What's New
Question of the Week
- 2017 Archive
- 2016 Archive
Vaccine Index
Topic Index
Love the Question of the Week?
Receive it every week in your inbox
Each week, IAC Express will highlight a new, topical, or important-to-reiterate Q&A. IAC works with CDC to select the "Question of the Week" based on commonly asked questions.
Please forward the "Question of the Week" to your colleagues and ask them to subscribe to IAC Express.
>> Subscribe to IAC Express!
Submit a Question to Ask the Experts
You can email your question about vaccines or immunization to IAC. As we receive hundreds of emails each month, we cannot guarantee that we will print your specific question in the Ask the Experts feature. However, you will get an answer. You can also email CDC's immunization experts directly at nipinfo@cdc.gov. There is no charge for this service.
email a question
- Guide to immunize.org -
Combination Vaccines
Hepatitis A
Hepatitis B
Question of the Week
Vaccine Storage and Handling
What's New
>> view all
Administering Vaccines
Documenting Vaccination
Scheduling Vaccination
Screening for Contraindications
Storage & Handling
Vaccine Recommendations
>> view all
Hepatitis A
Hepatitis B
>> view all
Administering Vaccines
Adult Vaccination
Documenting Vaccinations
Managing Vaccine Reactions
Parent Handouts
Patient Schedules
Questions & Answers
Screening Checklists
Standing Orders
Storage & Handling
Supplies Checklist
Talking with Parents
Temperature Logs
Top Handouts
Vaccine Index
>> view all
HepB Birth Dose
Influenza Vaccination for HCP
>> view all
IAC Express
Needle Tips
Vaccinate Adults
Immunization Techniques DVD
Laminated Schedules
Patient Record Cards
The Vaccine Handbook:
  A Practical Guide for Clinicians
>> view all
State Websites
State Laws
State Immunization Managers
>> view all
Hepatitis A
Hepatitis B
>> view all
Adjuvants & Ingredients
Alternative Medicine
Importance of Vaccination
>> view all
Vaccine Index
>> view all
>> view all
Web Sections
>> view all
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 6NH23IP22550) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.